Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk ASWBO:NNO2 -2.03%80 Price-to-Owner-Earnings is 10.45 as of Aug. 11, 2026, which is 51% below its 10-year median of 21.39. GuruFocus rates WBO:NNO2 with a GF Score™ of 80/100 and a GF Value™ of €93.42 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 463 Drug Manufacturers companies, Novo Nordisk AS ranks better than 79.27% on this metric.
As of today (2026-08-11), Novo Nordisk AS's share price is €40.855.
Novo Nordisk AS's Owner Earnings per Share (TTM) ended in Jun. 2026 was €3.91. It's Price-to-Owner-Earnings for today is 10.45.
The historical rank and industry rank for Novo Nordisk AS's Price-to-Owner-Earnings or its related term are showing as below:
WBO:NNO2'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.21 Med: 21.39 Max: 57.29
Current: 10.44
During the past 13 years, the highest Price-to-Owner-Earnings of Novo Nordisk AS was 57.29. The lowest was 8.21. And the median was 21.39.
WBO:NNO2's Price-to-Owner-Earnings is ranked better than 79.27% of 463
companies
in the Drug Manufacturers industry
Industry Median: 23.79
vs WBO:NNO2: 10.44
Novo Nordisk AS Price-to-Owner-Earnings Related Terms
Novo Nordisk AS Price-to-Owner-Earnings Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:NNO2 vs LLY, JNJ, ABBV: Price-to-Owner-Earnings Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Price-to-Owner-Earnings vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Novo Nordisk AS's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Owner-Earnings of 10.45 mean?
Novo Nordisk AS (WBO:NNO2) has a Price-to-Owner-Earnings of 10.45 as of Aug. 11, 2026. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Novo Nordisk AS and its competitors. This is 51% below median its historical median of 21.39. Over the past decade, Novo Nordisk AS's Price-to-Owner-Earnings has ranged from 8.21 to 57.29. According to the industry distribution chart, Novo Nordisk AS ranks #96 out of 463 companies in the Drug Manufacturers industry, placing it in the top 20.7%.
Is Novo Nordisk AS's Price-to-Owner-Earnings too high?
Novo Nordisk AS's current Price-to-Owner-Earnings of 10.45 is 51% below median its 10-year median of 21.39. Over the past 10 years, this metric has ranged from a low of 8.21 to a high of 57.29. The Drug Manufacturers industry median Price-to-Owner-Earnings is 23.79. Novo Nordisk AS's value of 10.45 is 56.1% below this industry median. Based on the distribution chart, Novo Nordisk AS ranks #96 out of 463 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Price-to-Owner-Earnings compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #96 out of 463 companies for Price-to-Owner-Earnings. This places Novo Nordisk AS in the top 21% of its industry — outperforming the majority of peers. The industry median Price-to-Owner-Earnings is 23.79. Novo Nordisk AS's value of 10.45 is 56.1% below this benchmark. Historically, Novo Nordisk AS's own Price-to-Owner-Earnings has ranged from 8.21 to 57.29 over the past decade. While the company's 10-year median is 21.39 vs. the industry median of 23.79, Novo Nordisk AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Owner-Earnings for a Drug Manufacturers company?
The median Price-to-Owner-Earnings among Drug Manufacturers companies is 23.79, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Owner-Earnings significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Owner-Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Price-to-Owner-Earnings of 10.45 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Owner-Earnings mean?
A high Price-to-Owner-Earnings can signal that a stock is expensive relative to its fundamentals. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Price-to-Owner-Earnings is 23.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Price-to-Owner-Earnings is 10.45, which is 51% below median its own 10-year median of 21.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €93.42, compared to a current price of €40.86 — trading 56.3% below its estimated fair value. The current Price-to-Owner-Earnings is 10.45, which is 51% below median its 10-year median of 21.39 and 56.1% below the Drug Manufacturers industry median of 23.79. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Owner-Earnings calculated?
Price-to-Owner-Earnings is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Price-to-Owner-Earnings is 10.45 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €40.86 is trading 56.3% below its estimated GF Value™ of €93.42.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Price-to-Owner-Earnings: 10.45 (51% below median its 10-year median of 21.39)
GF Value™: €93.42 vs. price of €40.86 (56.3% below fair value)
Industry Position: 56.1% below the Drug Manufacturers median (#96 of 463)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score
Get the complete analysis for WBO:NNO2
Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
